At least 17 biotechs and pharmas reported earnings last week. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) lost $2.8 billion in market value on the week after lowering its guidance for the fiscal year ended March 31, 2014. The pharma now expects net sales of ¥1.59 trillion ($16 billion) in FY13, down from ¥1.63 trillion previously, and net income of ¥95 billion ($958 million), down from ¥150 billion. Takeda attributed the lowered guidance to a number of factors, including "strengthening of government measures to constrain medical expenditure," the faster than expected penetration of generics in Japan and the recall in February of anemia drug Omontys peginesatide by Takeda and partner Affymax Inc. (NASDAQ:AFFY). Takeda also noted that Deborah Dunsire will retire as president and CEO of Takeda's Millennium Pharmaceuticals Inc. subsidiary. Anna Protopaps, EVP and global business development head at the pharma's Takeda Pharmaceutical International Inc. subsidiary, will become president of Millennium.

Dendreon Corp. (NASDAQ:DNDN) and Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) both fell 15% last week after reporting disappointing sales of their main drugs. Net revenues for Dendreon's prostate cancer product Provenge sipuleucel-T fell 18% to $67.6 million, below the Street's estimate of $79.7 million. Sales of Optimer's antibiotic Dificid fidaxomicin were up 17% to $16.8 million, but shy of the Street's $19.7 million estimate. Myriad Genetics Inc. (NASDAQ:MYGN) gained 19%, or $415 million in market cap, after beating the Street's revenue and earnings projections. The molecular diagnostic company also raised its 2013 revenue and earnings guidance. (A) Fiscal 4Q earnings; (B) Fiscal 3Q earnings; Mcap in $M